OptiBiotix Signs Major Supply Agreement For Its Microbiome Modulating Cholesterol-Reduction Probiotic

OptiBiotix, a world leader in microbiome modulation, has signed a three-year supply agreement with HLH BioPharma Vertriebs GmbH for its cholesterol-reducing LPLDL® probiotic supplement. Research into the LPLDL® probiotic, presented at Vitafoods Europe in May 2017, demonstrated that it is a safe natural ingredient which reduces blood pressure and cholesterol, key determinates of cardiovascular risk. The probiotic was found to reduce LDL cholesterol by up to 13.9%, and blood pressure by 5.1%. This research was carried out by Glenn Gibson, Professor of Food Microbiology, Head of Food Microbial Sciences at University of Reading.

Stephen O’Hara, CEO of OptiBiotix, commented, “The development of our LPLDL® probiotic product has made cholesterol reduction through microbiome modulation a reality, and we are thrilled to be working with HLH, one of Europe’s leading suppliers to the pharmacy market, on this product. The ability to create designer active ingredients which can modify an individual’s microbiome to improve health places OptiBiotix at the forefront of global microbiome research and product development, and we anticipate many more opportunities for the LPLDL® probiotic.”

Microbiome modulators in the form of probiotic supplements, like LPLDL®, may be the way forward for managing long term conditions like cardiovascular disease. The reduction of both LDL cholesterol and blood pressure is key for managing the risk of cardiovascular disease. The combination of high blood pressure and cholesterol deposition may lead to the chronic inflammation and hardening of the walls of the blood vessels, which greatly increases the probability of suffering a cardiovascular event. Recent research, presented at the European Society of Cardiology Congress 2016, demonstrated that reducing LDL cholesterol and blood pressure can reduce the lifetime risk of cardiovascular disease by nearly 90% [i]. The supply agreement grants HLH a non-exclusive license to produce, package, and commercialise products containing the LPLDL® strain, and follows HLH’s recent order for 100,000 units of LPLDL®. HLH has over 20 years’ experience in the distribution of probiotic and natural products under the brand names Lactobact® and Casa Sana® and is one of Europe’s leading suppliers of probiotics to the pharmacy market. The company is based in Germany and has established an international reputation for providing high quality and scientifically validated innovative products. LPLDL® will be supplied as bulk capsules which will be packaged and branded as part of HLH’s market leading Lactobact® brand.

FOR MEDIA INFORMATION:
On behalf of Optibiotix Health plc
Simon Vane Percy
Vane Percy & Roberts
(T) +44 (0) 1737 821890
(e) simon@vanepercy.com

The human microbiome

The human digestive tract contains a complex and diverse ecosystem of trillions of bacteria. Recently, advances in molecular and analytical techniques (metagenomics, metabolomics) have permitted identification and quantitation of species and strains of bacteria that inhabit the gastrointestinal tract, their metabolic activity, and interactions with the human host. These studies have provided greater insight into the role of gut and their metabolites in health and disease.

NIH https://commonfund.nih.gov/hmp/index

Web MD http://www.webmd.com/digestive-disorders/what-your-gut-bacteria-say-your-health#1

About OptiBiotix

OptiBiotix was formed in March 2012 by Stephen O’Hara to develop compounds which modify the human microbiome – the collective genome of the microbes in the body – to prevent and manage human disease.

The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.

OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.

www.optibiotix.com

Back to news